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The problem of cancer remains one of the most immense challenges to current biomedical research.
Affecting populations in all countries and all regions, this disease is responsible formillions of deaths
annually (1). Evasion of the immune system is an ominous feature of cancers, which often leads to
tumor outgrowth, epithelial–mesenchymal transition (EMT), and consequently, metastatic disease.
The need to understand basic mechanisms governing immune response to tumors is increasingly
acute, since contemporary cancer research gradually progresses toward highly specialized person-
alized medicine. In this respect, oncoimmunology of pattern recognition receptors (PRRs) is a
promising area of research which requires more attention and broader interpretation.
The group of PRRs includes families of toll-like receptors (TLRs), NOD-like receptors (NLRs),
C-type lectin receptors (CLRs), RIG-I-like receptors (RLRs), and AIM-2-like receptors (ALRs).
United by two general features, these receptors are the key players in human immunity. First,
they directly recognize antigen determinants of nearly all classes of pathogens [pathogen-associated
molecular patterns (PAMPs)] and promote their elimination by triggering innate and adaptive
immune response. Second, they recognize endogenous ligands released during cell stress [damage-
associatedmolecular patterns (DAMPs)], and therefore can activate immune response in the absence
of an infectious agent. In addition, PRRs are known to possess a number of other vital functions, reg-
ulating the processes of apoptosis, DNA repair, autophagy, and angiogenesis. Remarkable functional
significance and diversity of biological functions are the reasons why PRRs today are an actively
growing area of research.
During the last decade, much research has been done to investigate the role of PRRs in
tumor immunity. Accumulating evidence demonstrate that anti-tumor immunity can be stimulated
through the activation of PRRs (2, 3). It has been repeatedly shown that reinforced PRR activation
may protect the host from infectious agents and prevent, inhibit, or block carcinogenesis whereas
disrupted or deregulated functioning of PRRs may promote cancer through weakening the immune
system (2, 3). At the same time, PRR activation may stimulate cancer by creating a proinflammatory
microenvironment which is favorable for tumor progression and chemoresistance development
(4). Furthermore, it may also result in immunosuppression caused by chronic inflammation (2),
which is known to promote the development of breast carcinoma, colorectal cancer, pancreatic
adenocarcinoma, and possibly several other cancer types (5, 6). In this case, on the contrary,
lower PRR activity should minimize effects of chronic inflammation such as enhancement of
cancer initiation and promotion/progression and, consequently, decrease probability of tumor
development (4). Therefore, the situation resembles a double-edged sword, where both sides can cut
unless goldenmean ismaintained. In this respect, it is clear that a subtle balance of low and high PRR
activity is required for proper functioning of the immune system. This hypothesis, initially developed
for PRRs (3), may also be successfully projected on PRR intracellular signaling pathways – if
their elements are overexpressed/constantly activated, it may lead to consequences similar to that
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of enhanced PRR activation (7, 8). On the other hand, if down-
stream members of PRR pathways are underexpressed, inacti-
vated, or unable to work properly, it may result in the same
effects that of diminished PRR activity, and therefore a balance in
functioning of all genes encoding proteins constituting PRR sig-
naling pathways should be preserved for optimal immune system
function (7, 8).
Three years ago, four milestone reviews on PRR biology were
published in Immunity (9–12); we now think that Frontiers in
Immunology can be an excellent platform for the constellation
of review articles systematizing key information in the field with
regard to the recent discoveries. With this aim in mind, we invited
a number of recognized experts in the field to submit review
papers on various aspects of PRR biology and their role in cancer.
We sincerely thank all researchers who have agreed to contribute
to our Research Topic.
This collection is divided into three sections. The first section
describes basic functions of PRRs along with their signaling path-
ways, and was established with the participation of Taro Kawai
and colleagues, Mansi Saxena and Garabet Yeretssian, Huimin
Yan and colleagues, together with Stephanie Reikine, Jennifer
Nguyen, and Yorgo Modis. We also sought to solicit a number
of additional review articles on TLR and NLR biology, since
we believe these topics deserve a particular attention. Regarding
TLRs, Ajay Jain, Sabina Kaczanowska, and Eduardo Davila depict
the newest schemes of the IL-1 receptor-associated kinase signal-
ing, whereas Asif Amin Dar, Rushikesh Sudam Patil, and Shub-
hada Vivek Chiplunkar provide the insights into the relationship
between TLRs and γδ T cell response. Readers interested in
NLR structure and functioning will definitely appreciate elegant
papers by Irving Coy Allen, Julie Magarian Blander, and Andrew
Kent together with Silvia Lucena Lage and colleagues. In addi-
tion, a brilliant review by Nelson Di Paolo fills a substantial gap
in the understanding of the recognition of human oncogenic
viruses by PRRs. Finally, Raunaq Singh Nagi, Ashish Bhat, and
Himanshu Kumar close up the first section with the descrip-
tion of the general conception on the role of PRRs in cancer
development.
The second section is devoted to the role of PRRs in various vital
cellular processes, including apoptosis, DNA repair, autophagy,
and angiogenesis. It is contributed by Gustavo Amarante-Mendes
and colleagues, Anton Kutikhin and colleagues, Ji Eun Oh, and
Heung Kyu Lee along with Sheeba Murad.
Finally, the last piece of the collection consists of reviews that
comprehensively analyze the impact of PRRs on the development
of malignant tumors (esophageal cancer, gastric cancer, colorectal
cancer, lung cancer, prostate cancer, breast cancer, ovarian cancer,
and lymphoma). Furthermore, Simon Heidegger and colleagues
discuss the role of PRRs in graft-versus-host disease and graft-
versus-leukemia following allogeneic stem cell transplantation. As
a final point, Shanjana Awasthi underlines the importance of TLR
agonists in cancer immunotherapy.
We created this Research Topic with the hope that it will be
useful for a wide audience, particularly cancer researchers, immu-
nologists, microbiologists, graduate, and undergraduate students
of biomedical faculties as well as for their lecturers.
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